NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Gossamer Bio, Inc. (GOSS) Stock Analysis

Gossamer Bio, Inc. (GOSS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GOSS

$9.79

+$0.21 (+2.19%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GOSS with… →

GOSS Key Statistics

As of Oct 21, 2026
Trading
Open
$9.50
Previous Close
$9.58
Day's Range
9.50–10.35
52-Week Range
8.29–309.60
Volume
218.88K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.21
Valuation
Market Cap
$59.88M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.12
EPS (ttm)Profit attributable to each share over the last twelve months.
−52.80
Financials (FY)
Revenue (FY)
$48.47M−57.74%
Net Income (FY)
−$170.37M
Profit marginThe share of revenue left as profit after all costs and taxes.
−235.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
6.12M
1-Year Return
−94.39%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
373.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GOSS closed at $9.79, −94.39% over 1 year.

Gossamer Bio, Inc. (GOSS) has a market capitalization of $59.88M.

In fiscal 2025, GOSS reported revenue of $48.47M.

GOSS Stock Return by Calendar Year

Gossamer Bio, Inc. (GOSS) return since Feb 2019: what $10,000 became

1 year
$10,000 $561
−94.39%
5 years
$10,000 $97
−99.03%
Since Feb 2019
$10,000 $68
−99.32%

If you had invested $10,000 in Gossamer Bio, Inc. (GOSS) at the close on February 8, 2019, the earliest close on record here, it would have been worth $68 at the close on October 21, 2026: −99.32% in total, −47.68% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−96.05%
2025+242.54%
2024−0.88%
2023−57.93%
2022−80.81%
2021+16.96%
2020−38.13%
2019 (partial year)−12.88%

As of October 21, 2026.

GOSS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$48.47M−$170.37M−351.5%
2024$114.70M−$56.53M−49.3%
2023$0.00−$179.82M—
2022$0.00−$229.38M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$48.47M—−$163.25M−$170.37M−351.5%
2024$114.70M—−$59.92M−$56.53M−49.3%
2023$0.00—−$173.76M−$179.82M—
2022$0.00—−$218.53M−$229.38M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GOSS Valuation vs Biotechnology Median

Median of 608 stocks
MetricGOSSBiotechnology medianvs median
P/S ratio1.1213.300.1x the median
Profit margin−235.00%−38.31%196.7 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Gossamer Bio, Inc. (GOSS) at $59.88M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 161 employees.

The most recent close on file for GOSS is $9.79, dated October 21, 2026. That is +$0.21 (+2.19%) against the previous close. The 52-week range on file runs from $8.29 to $309.60. The latest close sits 18.09% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $48.47M. That is −57.74% against the prior fiscal year, when revenue was $114.70M. The same year closed with a net loss of $170.37M. The reported profit margin is −235%. That is 196.7 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −52.8.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $48.47M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.12. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −94.39%. Across 5 years the annualized return works out at −60.46%. Beta against the wider market is reported at 2.21. Daily returns over the trailing 7 years annualize to a volatility of 97.83%.

Growth & Income

No dividend is on file for GOSS.

The strongest complete calendar year on file is 2025 at +242.54%; the weakest is 2022 at −80.81%. Of the 6 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −96.05% year to date.

Peer Comparison

Gossamer Bio, Inc. (GOSS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Gossamer Bio, Inc. GOSS $59.88M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Gossamer Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Visit website →